Skip to main content
For Healthcare Professionals
Banner-Background

URGENCY TO TREAT

IPF is a progressive, fibrotic, and ultimately fatal condition with an unknown cause1,2

IPF, the most prevalent form of ILD, leaves patients at risk for:
Worsening symptoms
Worsening symptoms3,4
  • Cough
  • Dyspnea
  • Fatigue
Lung function decline
Lung function decline5,6
  • Patients on previously approved antifibrotics continue to lose approximately 100 mL of FVC annually
Early death
Early death7
  • The 5-year survival rate is less than 40%
Quicklinks

FVC, forced vital capacity; ILD, interstitial lung disease; IPF, idiopathic pulmonary fibrosis.

TREATMENT BURDEN

A heavy treatment burden adds challenges in IPF care, including8,9:

Discontinuations due to debilitating side effects
Discontinuations due to debilitating side effects10
  • Higher discontinuation rates observed in real-world studies1
Physical and emotional burden
Physical and emotional burden
  • Difficulty doing everyday tasks4
  • Numerous tests/liver monitoring required8,11
  • Supplemental oxygen use4,8

As the prevalence of IPF increases, more patients will seek a treatment that’s well tolerated with benefits beyond reduction in FVC decline1

Discover the data
Quicklinks
References

  1. Strykowski R, Adegunsoye A. Idiopathic pulmonary fibrosis and progressive pulmonary fibrosis. Immunol Allergy Clin North Am. 2023;43(2):209-228.

  2. Castelino FV, Moua T. Detection and management of interstitial lung diseases associated with connective tissue diseases. ACR Open Rheum. 2021;3(5):295-304.

  3. Reichmann WM, Yu YF, Macaulay D, Wu EQ, Nathan SD. Change in forced vital capacity and associated subsequent outcomes in patients with newly diagnosed idiopathic pulmonary fibrosis. BMC Pulm Med. 2015;15:167.

  4. Swigris JJ, Brown KK, Abdulgawi R, et al. Patients’ perceptions and patient-reported outcomes in progressive-fibrosing interstitial lung diseases. Eur Respir Rev. 2018;27(150):180075.

  5. Crestani D, Huggins JT, Kaye M, et al. Long-term safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis: results from the open-label extension study, INPULSIS-ON. Lancet Respir Med. 2019;7(1):60-68.

  6. Wuyts WA, Bonello F, Chaudhuri N, et al. Continued nintedanib treatment in patients with progressive fibrosing ILDs: interim analysis of INBUILD-ON. Poster presented at: European Respiratory Society International Congress; September 4-6, 2022; Barcelona, Spain.

  7. Xu F, Tong Y, Yang W, et al. Identifying a survival-associated cell type based on multi-level transcriptome analysis in idiopathic pulmonary fibrosis. Respir Res. 2024;25(1):126.

  8. Data on file. Boehringer Ingelheim International GmbH. ILD Patient Journey PPT.

  9. Data on file. Boehringer Ingelheim International GmbH. PF Situation Analysis 2024.

  10. Delameillieure A, Wuyts WA, Pironet A, Dobbels F. Electronically monitored medication adherence in idiopathic pulmonary fibrosis: prevalence, predictors and outcomes. ERJ Open Res. 2022;8(3):00030-2022.

  11. National Institute of Diabetes and Digestive and Kidney Diseases. Nintedanib. In: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda, MD: National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. Updated December 12, 2023. Accessed March 24, 2026. https://www.ncbi.nlm.nih.gov/books/NBK548135.

MLR ID: PC-AE-102892
Expiry Date: 10/05/2028